Cyprium Therapeutics Inc.

The US FDA’s user fee calendar for 2024 already features almost 60 new molecular entities and novel biologics, echoing the agency’s review workload at the beginning of 2023 – a position that contains

“If we don’t change, we don’t grow” said American author and journalist Gail Sheehy. In February, Zydus Cadila (Cadila Healthcare Ltd) shed a 27-year-old identity to emerge as Zydus Lifesciences Ltd

On 24 May 2021, Zydus Cadila launched the world's first antibody drug conjugate (ADC) biosimilar to Roche Holding AG / Genentech, Inc. ’s Kadcyla (trastuzumab emtansine), under the name Ujvira to t

In a quiet week for approvals, the US Food and Drug Administration acted in two relatively underserved areas: the common condition bacterial vaginosis, where the FDA cleared Daré Biosciences’ Xaciato,